Edgewise Therapeutics Files 2025 Proxy Statement
Ticker: EWTX · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: EWTX
TL;DR
Edgewise Therapeutics (EWTX) proxy filed. Vote on directors & auditors for June 13 meeting.
AI Summary
Edgewise Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting of stockholders scheduled for June 13, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.
Why It Matters
This filing is crucial for shareholders as it details how the company is run, executive pay, and what matters will be voted on at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing, which is standard for public companies and does not inherently introduce new risks.
Key Numbers
- 20250613 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250429 — Filing Date (The definitive proxy statement was filed on this date.)
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Registrant
- 0001710072 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 001-40236 (company) — SEC File Number
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing details on matters to be voted upon, such as director elections and executive compensation.
When is Edgewise Therapeutics' annual meeting of stockholders?
The annual meeting of stockholders for Edgewise Therapeutics is scheduled for June 13, 2025.
What type of company is Edgewise Therapeutics, Inc. based on its SIC code?
Edgewise Therapeutics, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this definitive proxy statement?
The definitive proxy statement (DEF 14A) for Edgewise Therapeutics, Inc. was filed on April 29, 2025.
Where is Edgewise Therapeutics, Inc. headquartered?
Edgewise Therapeutics, Inc. is headquartered in Boulder, Colorado, with its business and mailing address listed as 1715 38th St, Boulder, CO 80301.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Edgewise Therapeutics, Inc. (EWTX).